Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)

Completed · Phase 1/Phase 2

Conditions studied: Child Development Disorders, Pervasive

In brief

The purpose of this study is to determine if the known differences in genes influence drug metabolizing enzymes and receptors that are involved in risperidone drug action. The study will determine if differences in these genes will change the concentration of risperidone in the blood over time in children in relation to side effects and clinical response to risperidone.

Key facts

Study ID
NCT00166595
Run by
Children's Hospital Medical Center, Cincinnati
People needed
100
Starts
2003-02-01
Expected to finish
2005-03-01
Last updated by the study team
2014-01-28

Who can join

Age: 4 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.